Unicycive Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
UNCY$3.66-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
UNICYCIVE THERAPEUTICS, INC.
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Audited Financial Statements for the years ended December 31, 2024 and 2025: | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID #606) | F-2 |
| Balance Sheets as of December 31, 2024 and 2025 | F-3 |
| Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2025 | F-4 |
| Statements of Mezzanine Equity and Stockholders’ (Deficit) Equity for the years ended December 31, 2024 and 2025 | F-5 |
| Statements of Cash Flows for the years ended December 31, 2024 and 2025 | F-6 |
| Notes to the Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.